Radiotherapy/CAR T Combo May be “Great Option” in Relapsed/Refractory DLBCL

Commentary
Video

No evidence indicates synergistic toxicity when combining radiation with CAR T-cell therapy in this population, according to Timothy Robinson, MD, PhD.

CancerNetwork® spoke with Timothy Robinson, MD, PhD, about the key takeaways of a presentation he gave at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting on how radiation may be incorporated as bridging therapy in combination with CAR T-cell therapy among patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Describing this combinational strategy as a “great option”, Robinson, an assistant professor of therapeutic radiology at Yale Cancer Center, emphasized there was no evidence of synergistic toxicity when administering radiotherapy plus CAR T-cell therapy in this population. Additionally, he stated that this approach may be considered for patients with a single site of disease and suggested that others in the field should educate patients so that they can know about the use of CAR T-cell therapy more broadly.

Transcript:

I would say a couple of things. One, don’t be afraid of radiation and CAR T. As I mentioned, there’s no evidence of synergistic toxicity, and this can be an effective way just to get somebody to the starting block. That’s the first big takeaway message: for patients who need a bridge from point A to point B, this is a great option.

Two, for patients with relatively localized disease, this is something we can think about. This is an area of ongoing, evolving treatment. But if you’ve got a patient with 1 site of disease—that’s the only thing they have, and it’s a high-risk spot—bridging radiation is becoming a standard at tertiary care centers who treat a lot of [these patients].

Lastly, I would say to just keep an eye out. You [should] get patients to know more broadly about CAR T and how it works. CAR T, right now, for lymphoma, is approved in the [second or] third line for patients who have primary refractory disease—meaning that before they even finished chemotherapy, their disease was coming back—or early relapse [when patients] finish chemotherapy and the disease is gone, but within 12 months, it’s back. If it’s early relapsed or refractory disease, those patients are also eligible for CAR T therapy.

If you have a patient and their disease is just not responding to chemotherapy, more chemotherapy is not the answer. Figuring out how to get that patient to CAR T and how radiation can be helpful in that [treatment] is the big takeaway on that front.

Reference

Robinson T. Radiotherapy’s effective incorporation with chimeric antigen receptor (CAR)-T cell therapy for relapsed/refractory diffuse large B-cell lymphoma. Presented at: 2024 American Society for Radiation Oncology Annual Meeting; September 29-October 2, 2024; Washington, DC.

Recent Videos
The Together for Supportive Cancer Care coalition may advance the national conversation in ensuring comprehensive care for all patients with cancer.
Health care organizations have come together to form the Together for Supportive Cancer Care coalition to address gaps in supportive cancer care services.
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Patients treated with BCMA-directed immunotherapies for myeloma may experience susceptibility to severe infections following treatment.
BCMA testing tracks clinical changes faster without the need for marker expression vs monoclonal immunoglobulin, a conventional multiple myeloma marker.
Studies indicate that higher BCMA levels are associated with a greater need for therapy years following diagnosis for patients with smoldering myeloma.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Related Content